TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24690201

Group type: EXPERIMENTAL
Intervention: Preventive treatment (clinician controlled), receiving care on a regular basis
Number of subjects: 400

Group type: COMPARATOR
Intervention: Symptom-guided treatment (patient controlled), receiving care when patients feel a need
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Preventive treatment (clinician controlled)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Symptom-guided treatment (patient controlled)
Number of subjects: 400
Study: 21744032

Group type: EXPERIMENTAL
Intervention: Mild Alzheimer's disease (AD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moderate Alzheimer's disease (AD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Severe Alzheimer's disease (AD)
Number of subjects: 100
Study: 20305098

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 44
Study: 18607963

Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin treatment
Number of subjects: 0
Study: 16322468

Group type: EXPERIMENTAL
Intervention: Total therapy 2 without thalidomide (TT2)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Total therapy 1 (TT1)
Number of subjects: 345
Study: 12936973

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg single oral dose
Number of subjects: 24
Study: 10867849

Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 150
Study: 8781902

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal band ligation (EVL)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 68
Study: 1622642

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 2 years
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Perioperative cyclophosphamide
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 2000
Study: 6372563

Group type: EXPERIMENTAL
Intervention: Captopril and furosemide
Number of subjects: 2

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Captopril followed by furosemide
Number of subjects: 2
Study: 30368338

Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique (INIT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study: 27546745

Group type: COMPARATOR
Intervention: suture + BPU (control)
Number of subjects: 221
Study: 24502830

Group type: EXPERIMENTAL
Intervention: Cladribine 5.25 mg/kg
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 21499876

Group type: EXPERIMENTAL
Intervention: Pilates exercise program (1 hour, 3 times a week for 12 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard treatment programs (control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 55
Study: 20007923

Group type: EXPERIMENTAL
Intervention: BIBW 2948 (15 mg twice a day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BIBW 2948 (30 mg twice a day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 18673350

Group type: EXPERIMENTAL
Intervention: Acetaminophen and diphenhydramine
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 15910627

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Insulin-treated Type 2 diabetes
Number of subjects: 267
Study: 12632426

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin plus low-dose aspirin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 40
Study: 10528065

Group type: EXPERIMENTAL
Intervention: Totally laparoscopic aortic surgery (both transperitoneal and retroperitoneal approaches)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open vascular surgery
Number of subjects: 0
Study: 8785254

Group type: EXPERIMENTAL
Intervention: Rifabutin in combination with isoniazid, ethambutol, and clofazimine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rifabutin in multidrug regimens
Number of subjects: 50
Study: 1718367

Group type: EXPERIMENTAL
Intervention: Zinc supplements (30 mg/d for 3 d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 6355046

Group type: EXPERIMENTAL
Intervention: vidarabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 0
Study: 28986029

Group type: EXPERIMENTAL
Intervention: Daily regimen
Number of subjects: 191

Group type: COMPARATOR
Intervention: Time-driven regimen
Number of subjects: 191

Group type: COMPARATOR
Intervention: Event-driven regimen
Number of subjects: 191
Study: 27157292

Group type: EXPERIMENTAL
Intervention: Same-day discharge (SD), n = 50
Number of subjects: 493

Group type: COMPARATOR
Intervention: Delayed discharge (DD), n = 50
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Same-day discharge (SD)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Delayed discharge (DD)
Number of subjects: 493
Study: 25127090

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous hydrocortisone infusion (CSHI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral hydrocortisone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CSHI
Number of subjects: 10
Study: 22978561

Group type: EXPERIMENTAL
Intervention: Housing First intervention (Assertive Community Treatment for high needs participants and Intensive Case Management for moderate needs participants)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Treatment as Usual (control)
Number of subjects: 575
Study: 20520291

Group type: EXPERIMENTAL
Intervention: Assessment at 2 weeks
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Assessment at 4 weeks
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Assessment at 6 weeks
Number of subjects: 299
Study: 18031315

Group type: EXPERIMENTAL
Intervention: Pioglitazone (7.5 mg/day) added to flutamide (62.5 mg/day) and metformin (850 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 38
Study: 15919695

Group type: EXPERIMENTAL
Intervention: Daily haemodialysis (DHD) - 2-3 hours, 6 times/week
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard haemodialysis (SHD) - 4-5 hours, 3 times/week
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Daily haemodialysis (DHD)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard haemodialysis (SHD)
Number of subjects: 37
Study: 12640217

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 44
Study: 11471639

Group type: EXPERIMENTAL
Intervention: 400 mg of etodolac
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 600 mg of ibuprofen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9094887

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid (PUFA) ingestion (0.1:1 and 0.5:1 ratios to n-6 PUFAs) for 1 month each
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid (PUFA) ingestion (low dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid (PUFA) ingestion (high dosage)
Number of subjects: 0
Study: 8104091

Group type: EXPERIMENTAL
Intervention: 2.5 mg IV bolus of etilefrine followed by continuous infusion (0.35 mg.kg‐1.h‐1)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 30 ml.kg‐1 infusion of saline isotonic solution for 90 min
Number of subjects: 148

Group type: COMPARATOR
Intervention: No preventive treatment (control group)
Number of subjects: 148
Study: 2883784

Group type: EXPERIMENTAL
Intervention: DTP vaccine, initial immunization at five months of age or later, second dose at eight weeks or more
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTP vaccine, initial immunization at ages less than five months
Number of subjects: 0
Study: 31323295

Group type: EXPERIMENTAL
Intervention: Soccer training + caloric-restricted diet (SDG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Caloric-restricted diet alone (DG)
Number of subjects: 51
Study: 30273901

Group type: EXPERIMENTAL
Intervention: Smartphone self-help application (Be Good to Yourself) for four weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Smartphone self-help application (Be Good to Yourself) for frequent users
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Smartphone self-help application (Be Good to Yourself)
Number of subjects: 90
Study: 26337853

Group type: EXPERIMENTAL
Intervention: Emotional facial expressions identification task using virtual emotional faces
Number of subjects: 107
Study: 24630820

Group type: EXPERIMENTAL
Intervention: Burn rehabilitation massage therapy
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard rehabilitation therapy for hypertrophic scars
Number of subjects: 146
Study: 22471132

Group type: EXPERIMENTAL
Intervention: Tolterodine 1 mg orally, twice a day + electroacupuncture (Baihui, Sishengcong, Yintang) once a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tolterodine 2 mg orally, twice a day
Number of subjects: 60
Study: 19825835

Group type: EXPERIMENTAL
Intervention: Evening administered bimatoprost/timolol fixed combination (BTFC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morning administered bimatoprost/timolol fixed combination (BTFC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bimatoprost monotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Evening BTFC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morning BTFC
Number of subjects: 60
Study: 17661244

Group type: EXPERIMENTAL
Intervention: Non-lifting sign
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Endoscopic assessment
Number of subjects: 239
Study: 15692986

Group type: EXPERIMENTAL
Intervention: Meloxicam 0.125 mg/kg body weight (single daily dose)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Meloxicam 0.25 mg/kg body weight (single daily dose)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Naproxen 10 mg/kg body weight (2 daily doses)
Number of subjects: 225
Study: 12685513

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day
Number of subjects: 133

Group type: COMPARATOR
Intervention: Nicardipine 60 mg/day (titrated to 10 mg/day if necessary)
Number of subjects: 133
Study: 10327211

Group type: EXPERIMENTAL
Intervention: Cellular and cytokine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 0
Study: 7720349

Group type: EXPERIMENTAL
Intervention: Five small hourly meals
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single larger meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Feeding (both meal regimens)
Number of subjects: 12
Study: 1904620

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 61

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 61
Study: 7188111

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg X 3/day/4 weeks p.o.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 31472669

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 60 mg.kg-1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 45
Study: 28157825

Group type: EXPERIMENTAL
Intervention: Local anesthesia before cervical punch biopsy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Cervical punch biopsy without local anesthesia
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Local anesthesia during biopsy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Injection of local anesthetic
Number of subjects: 204
Study: 25971958

Group type: EXPERIMENTAL
Intervention: Perioperative infection prevention bundle
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard infection prophylaxis
Number of subjects: 163
Study: 25382769

Group type: EXPERIMENTAL
Intervention: Nutrition consultation (PwH-I)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No intervention (PwH-O)
Number of subjects: 38
Study: 22305829

Group type: EXPERIMENTAL
Intervention: TAXUS Liberté stent with concomitant prasugrel therapy (1 year)
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Prasugrel plus aspirin (1 year)
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Prasugrel (5 and 10 mg daily doses)
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (12 versus 30 months)
Number of subjects: 4200
Study: 21163755

Group type: EXPERIMENTAL
Intervention: DD-I (patients before treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DD-II (patients after 8 weeks of pharmacological treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CG (control group)
Number of subjects: 30
Study: 17878470

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 16319260

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral iron polymaltose complex (300 mg elemental iron per day)
Number of subjects: 90
Study: 12411535

Group type: EXPERIMENTAL
Intervention: Antioxidants (AOX) ascorbic acid (2 g, I.V.) and alpha‐tocopherol (200 mg, P.O.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sham halothane with AOX
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham halothane with placebo
Number of subjects: 16
Study: 10445218

Group type: EXPERIMENTAL
Intervention: Iron plus zinc supplementation (12 mg/day of Fe+++ and 12.5 mg/day of Zn++)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12.5 mg/day of Zn++)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8575690

Group type: EXPERIMENTAL
Intervention: Vagifem (25 micrograms oestradiol) administered as vaginal pessaries daily, 3 weeks prior to surgery
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo administered as vaginal pessaries daily, 3 weeks prior to surgery
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Preoperative oestradiol group
Number of subjects: 43

Group type: COMPARATOR
Intervention: Preoperative placebo group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Preoperative oestradiol treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Preoperative placebo treatment
Number of subjects: 43
Study: 1976665

Group type: EXPERIMENTAL
Intervention: Terfenadine (H1-receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Histamine provocation challenge)
Number of subjects: 0
Study: 6761851

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 75
Study: 30663195

Group type: EXPERIMENTAL
Intervention: CKD‐EPIeGFR
Number of subjects: 17762

Group type: EXPERIMENTAL
Intervention: BIS1eGFR
Number of subjects: 17762
Study: 28740213

Group type: EXPERIMENTAL
Intervention: Alanyl-Glutamine (AlaGln) supplementation in PD fluid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard PD fluid (Control)
Number of subjects: 6
Study: 26277381

Group type: EXPERIMENTAL
Intervention: Total saturated fatty acids, palmitoleic acid (16:1n-7), dihomo-γ-linolenic acid (20:3n-6), estimated stearoyl-CoA desaturase 1 and Δ6-desaturase (D6D) enzyme activities
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Total polyunsaturated fatty acid, linoleic acid (18:2n-6), elongase activity
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Estimated D6D activity, dihomo-γ-linolenic acid (20:3n-6)
Number of subjects: 1302
Study: 24865945

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) treatment for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 21623963

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Simvastatin (40mg)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg) plus Simvastatin (40mg)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 19042945

Group type: EXPERIMENTAL
Intervention: Feces stored at 4 degrees C for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feces stored at 37 degrees C for 72 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feces stored at 37 degrees C for any time
Number of subjects: 0
Study: 19358184

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (intravenous for 24 hours, followed by oral for 10 days)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Appendicectomy (surgery)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 369

Group type: COMPARATOR
Intervention: Appendicectomy
Number of subjects: 369
Study: 15718406

Group type: EXPERIMENTAL
Intervention: New Fourier-based approach to analyze blood pressure variability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional methods to compute blood pressure variability
Number of subjects: 0
Study: 12088166

Group type: EXPERIMENTAL
Intervention: Acute treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acute and maintenance treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Maintenance treatment
Number of subjects: 50
Study: 9643406

Group type: EXPERIMENTAL
Intervention: Thermal balloon endometrial ablation for 8-16 minutes
Number of subjects: 8
Study: 8187941

Group type: EXPERIMENTAL
Intervention: azelastine nasal spray 0.14 mg/nostril twice daily (0.56 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: cetirizine tablets 10 mg once daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: azelastine nasal spray
Number of subjects: 40
Study: 2432009

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 12068264

Group type: EXPERIMENTAL
Intervention: Bibliotherapy/drinking guidelines (n = 411); participants received two pamphlets with information about the effects of alcohol and guidelines for low-risk drinking and self-monitoring.
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Motivational enhancement/personalized feedback (n = 414); participants received personalized advice/feedback based on their assessment of drinking and related behaviors.
Number of subjects: 825

Group type: COMPARATOR
Intervention: Both interventions (combined);
Number of subjects: 825
Study: 30507549

Group type: EXPERIMENTAL
Intervention: Tissue oxygenation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foot care knowledge and practice for patients with diabetes mellitus
Number of subjects: 0
Study: 27849166

Group type: EXPERIMENTAL
Intervention: FR104 (0.02 mg/kg to 1.500 mg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: FR104
Number of subjects: 64
Study: 25061688

Group type: EXPERIMENTAL
Intervention: Nurse telehealth coaching for five sessions
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study: 22726372

Group type: EXPERIMENTAL
Intervention: D-dimer levels at admission in patients with severe CAP
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: D-dimer levels at admission in patients with clinical failure at day 30
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: D-dimer levels at admission in patients with early failure
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: D-dimer levels in non-survivors
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: D-dimer levels <500 μg/l
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: D-dimer levels as a predictor for clinical outcome at day 30
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: D-dimer levels as a predictor for 30-day mortality
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Addition of D-dimer levels to CURB-65
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Serial D-dimer levels between patients with clinical success or failure at day 30
Number of subjects: 147
Study: 21098580

Group type: EXPERIMENTAL
Intervention: Daily remote device monitoring (electrocardiogram, blood pressure, body weight) coupled with medical telephone support
Number of subjects: 710

Group type: COMPARATOR
Intervention: Usual care led by the patients' local physician
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Daily remote device monitoring
Number of subjects: 710

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 710
Study: 18248490

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg q.d.)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 16351673

Group type: EXPERIMENTAL
Intervention: Single steroid injection (methylprednisolone acetate) plus saline injection at 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double steroid injections (methylprednisolone acetate) at baseline and at 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (single and double injections)
Number of subjects: 40
Study: 11979570

Group type: EXPERIMENTAL
Intervention: Automated procedure for longitudinal measurement of tissue volume and relaxation times
Number of subjects: 5

Group type: COMPARATOR
Intervention: Manual segmentation by two radiologists
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Quantitative MR imaging measures
Number of subjects: 5
Study: 10505589

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7574001

Group type: EXPERIMENTAL
Intervention: 4% cocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% lidocaine in oxymetazoline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% tetracaine in oxymetazoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1752116

Group type: EXPERIMENTAL
Intervention: recombinant human superoxide dismutase (rhSOD)
Number of subjects: 32
Study: 7034861

Group type: EXPERIMENTAL
Intervention: Autogenous wart vaccine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 34